Marianne Antonius Jakobsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marianne Antonius Jakobsen has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Christian Nielsen
Department of Clinical Immunology Odense University Hospital Odense Denmark
7 shared publications- Torben Barington
Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
7 shared publications - Anette Bygum
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
4 shared publications Ulrik Sprogøe
Department of Clinical Immunology Odense University Hospital Odense Denmark
4 shared publications- Frederik Banch Clausen
Department of Clinical Immunology, Laboratory of Blood Genetics Copenhagen University Hospital Copenhagen Denmark
3 shared publications - Kristian Assing
Odense University Hospital 2 Department of Clinical Immunology Odense
3 shared publications
Latest Publications
- 26 October 2020
- Published by Wiley in Transfusion Medicine
- Vol. 30 (6) , 508-512
A novel ABO allele with a 21‐bp duplication identified in two unrelated European individuals with weak A expression
Objectives: To carry out genetic and serological analyses of a Swiss blood donor and a Danish patient carrying an aberrant ABO phenotype with weak A expression.Background: ABO is the most clinically important blood group system but also one of the most complex. The system antigens are determined by carbohydrate structures generated by A and B glycosyltransferases encoded by the ABO gene. Genetic variants of ABO may encode a glycosyltransferase with reduced activity, leading to weak expression of A antigen.Methods: Samples from two individuals were examined using genetic testing and extended immunohaematological evaluation, including standard serological methods, flow cytometry and analysis of plasma glycosyltransferase activity.Results: Both individuals were serologically determined to be AweakB. Genetic testing revealed that both were heterozygous for a novel ABO*A1.01‐like allele with an in‐frame duplication of 21 nucleotides in exon 7 (c.543_563dup), leading to the insertion of seven amino acids (QDVSMRR). Flow cytometric testing of native red blood cells (RBCs) showed very weak A antigen expression. This was in accordance with the enzyme activity test.Conclusion: In summary, we describe a novel A allele with a duplication of 21 nucleotides in exon 7 that significantly decreases the enzyme activity and leads to very weak expression of A antigen. (200 words)
- 26 October 2020
- Published by Wiley in Transfusion Medicine
- Vol. 30 (6) , 508-512
A novel ABO allele with a 21‐bp duplication identified in two unrelated European individuals with weak A expression
Objectives: To carry out genetic and serological analyses of a Swiss blood donor and a Danish patient carrying an aberrant ABO phenotype with weak A expression.Background: ABO is the most clinically important blood group system but also one of the most complex. The system antigens are determined by carbohydrate structures generated by A and B glycosyltransferases encoded by the ABO gene. Genetic variants of ABO may encode a glycosyltransferase with reduced activity, leading to weak expression of A antigen.Methods: Samples from two individuals were examined using genetic testing and extended immunohaematological evaluation, including standard serological methods, flow cytometry and analysis of plasma glycosyltransferase activity.Results: Both individuals were serologically determined to be AweakB. Genetic testing revealed that both were heterozygous for a novel ABO*A1.01‐like allele with an in‐frame duplication of 21 nucleotides in exon 7 (c.543_563dup), leading to the insertion of seven amino acids (QDVSMRR). Flow cytometric testing of native red blood cells (RBCs) showed very weak A antigen expression. This was in accordance with the enzyme activity test.Conclusion: In summary, we describe a novel A allele with a duplication of 21 nucleotides in exon 7 that significantly decreases the enzyme activity and leads to very weak expression of A antigen. (200 words)
- 17 February 2020
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (1) , 87-94
Male origin microchimerism and ovarian cancer
Background: Reduced risk of ovarian cancer is commonly ascribed to reduced exposure to endogenous hormones during pregnancy, using oral contraceptives or not using hormone replacement therapy. However, exposure to hormones alone account for less than half of all cases. Many women carry small amounts of male cells—known as male origin microchimerism—in their circulation and remarkable impacts of these cells on women’s health are being published. Here, we pursue the possibility that male origin microchimerism has a role in reducing ovarian cancer risk. Methods: We conducted a prospective case-cohort study using blood samples and questionnaire data from 700 women participating in the Danish Diet, Cancer, and Health cohort. Blood samples were analysed for Y chromosome presence as a marker of male microchimerism. We evaluated the association between male microchimerism and ovarian cancer, using weighted Cox regression models reporting hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results: Male microchimerism was detected in 46% of cases and 65.9% of controls. Women testing positive for male microchimerism had a reduced hazard rate of ovarian cancer compared with women testing negative (HR = 0.44, 95% CI: 0.29-0.68). We found no evidence of interaction with measures of hormonal exposures (P = 0.50). Conclusions: For the first time we report that women who test positive for male microchimerism in their circulation have reduced rates of ovarian cancer compared with women who test negative. Although the underlying mechanisms are presently unknown, we believe male microchimerism is potent in preventing ovarian cancer.
- 17 February 2020
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (1) , 87-94
Male origin microchimerism and ovarian cancer
Background: Reduced risk of ovarian cancer is commonly ascribed to reduced exposure to endogenous hormones during pregnancy, using oral contraceptives or not using hormone replacement therapy. However, exposure to hormones alone account for less than half of all cases. Many women carry small amounts of male cells—known as male origin microchimerism—in their circulation and remarkable impacts of these cells on women’s health are being published. Here, we pursue the possibility that male origin microchimerism has a role in reducing ovarian cancer risk. Methods: We conducted a prospective case-cohort study using blood samples and questionnaire data from 700 women participating in the Danish Diet, Cancer, and Health cohort. Blood samples were analysed for Y chromosome presence as a marker of male microchimerism. We evaluated the association between male microchimerism and ovarian cancer, using weighted Cox regression models reporting hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results: Male microchimerism was detected in 46% of cases and 65.9% of controls. Women testing positive for male microchimerism had a reduced hazard rate of ovarian cancer compared with women testing negative (HR = 0.44, 95% CI: 0.29-0.68). We found no evidence of interaction with measures of hormonal exposures (P = 0.50). Conclusions: For the first time we report that women who test positive for male microchimerism in their circulation have reduced rates of ovarian cancer compared with women who test negative. Although the underlying mechanisms are presently unknown, we believe male microchimerism is potent in preventing ovarian cancer.
- 16 January 2020
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 47 (1) , 45-53
Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma
Introduction: ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information. Objective: Here, we report a next generation sequencing (NGS)-based assay for predicting the prenatal ABO blood group. Materials and Methods: A total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-free DNA was PCR-amplified using 2 primer sets followed by NGS. NGS data were analyzed by 2 different methods, FASTQ analysis and a grep search, to ensure robust results. The fetal ABO prediction was compared with the known serological infant ABO type, which was available for 19 samples. Results: There was concordance for 19 of 19 predictable samples where the phenotype information was available and when the analysis was done by the 2 methods. For immunized pregnant women (n = 20), the risk of HDFN was predicted for 12 fetuses, and no risk was predicted for 7 fetuses; one result of the clinical samples was indeterminable. Cloning and sequencing revealed a novel variant harboring the same single nucleotide variations as ABO*O.01.24 with an additional c.220C>T substitution. An additional indeterminable result was found among the 6 test samples and was caused by maternal heterozygosity. The 2 indeterminable samples demonstrated limitations to the assay due to hybrid ABO genes or maternal heterozygosity. Conclusions: We pioneered an NGS-based fetal ABO prediction assay based on a cell-free DNA analysis from maternal plasma and demonstrated its application in a small number of samples. Based on the calculations of variant frequencies and ABO*O.01/ABO*O.02 heterozygote frequency, we estimate that we can assign a reliable fetal ABO type in approximately 95% of the forthcoming clinical samples of type O pregnant women. Despite the vast genetic variations underlying the ABO blood groups, many variants are rare, and prenatal ABO prediction is possible and adds valuable early information for the prevention of ABO HDFN.
- 16 January 2020
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 47 (1) , 45-53
Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma
Introduction: ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information. Objective: Here, we report a next generation sequencing (NGS)-based assay for predicting the prenatal ABO blood group. Materials and Methods: A total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-free DNA was PCR-amplified using 2 primer sets followed by NGS. NGS data were analyzed by 2 different methods, FASTQ analysis and a grep search, to ensure robust results. The fetal ABO prediction was compared with the known serological infant ABO type, which was available for 19 samples. Results: There was concordance for 19 of 19 predictable samples where the phenotype information was available and when the analysis was done by the 2 methods. For immunized pregnant women (n = 20), the risk of HDFN was predicted for 12 fetuses, and no risk was predicted for 7 fetuses; one result of the clinical samples was indeterminable. Cloning and sequencing revealed a novel variant harboring the same single nucleotide variations as ABO*O.01.24 with an additional c.220C>T substitution. An additional indeterminable result was found among the 6 test samples and was caused by maternal heterozygosity. The 2 indeterminable samples demonstrated limitations to the assay due to hybrid ABO genes or maternal heterozygosity. Conclusions: We pioneered an NGS-based fetal ABO prediction assay based on a cell-free DNA analysis from maternal plasma and demonstrated its application in a small number of samples. Based on the calculations of variant frequencies and ABO*O.01/ABO*O.02 heterozygote frequency, we estimate that we can assign a reliable fetal ABO type in approximately 95% of the forthcoming clinical samples of type O pregnant women. Despite the vast genetic variations underlying the ABO blood groups, many variants are rare, and prenatal ABO prediction is possible and adds valuable early information for the prevention of ABO HDFN.
- Open Access
- 25 December 2019
- Published by Wiley in Clinical Case Reports
- Vol. 8 (2) , 313-316
Association between neutropenia and IgG antineutrophil antibodies in a case of CD40LG deficiency due to two novel mutations
This case suggests a mechanistic rationale for the clinical efficacy of intravenous immunoglobulins (IVIG) in treating CD40 ligand (CD40L) deficiency associated neutropenia as it is the first reported instance of free and cell‐bound antineutrophil antibodies in a case of CD40L deficiency, accompanied by a prolonged and clinically severe neutropenia.
- 25 December 2019
- Published by Wiley in Clinical Case Reports
- Vol. 8 (2) , 313-316
Open AccessAssociation between neutropenia and IgG antineutrophil antibodies in a case of CD40LG deficiency due to two novel mutations
This case suggests a mechanistic rationale for the clinical efficacy of intravenous immunoglobulins (IVIG) in treating CD40 ligand (CD40L) deficiency associated neutropenia as it is the first reported instance of free and cell‐bound antineutrophil antibodies in a case of CD40L deficiency, accompanied by a prolonged and clinically severe neutropenia.
- Open Access
- 11 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224858
Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and ACEi-AE were included. The Q-genie tool was used to evaluate the quality of the study methodologies. Seven studies were included. With the exception of one whole genome study, all of the included studies were candidate gene association studies. Study quality assessment scores ranged from 36 to 55. One study was found to be of good quality, suggesting that the detected associations may be unreliable. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. Polymorphisms within XPEPNP2, BDKRB2–9/+ 9 and neprilysin genes, were reported to be associated with increased risk of ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.
- 11 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224858
Open AccessGenetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and ACEi-AE were included. The Q-genie tool was used to evaluate the quality of the study methodologies. Seven studies were included. With the exception of one whole genome study, all of the included studies were candidate gene association studies. Study quality assessment scores ranged from 36 to 55. One study was found to be of good quality, suggesting that the detected associations may be unreliable. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. Polymorphisms within XPEPNP2, BDKRB2–9/+ 9 and neprilysin genes, were reported to be associated with increased risk of ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.
- Open Access
- 4 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e231122
Acquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance
Angioedema (AE) is caused by a wide range of diseases and pharmaceuticals; it can become life-threatening when located to the airways. Patients with deficiency or malfunction of complement C1 esterase inhibitor (hereditary or acquired) experience recurrent AE due to an accumulation of the vasoactive mediator bradykinin (BK). Complement C1 inhibitor normally decreases BK production, so a reduced function hereof causes increased levels. The diagnosis of hereditary or acquired AE can be difficult due to similarities to allergic reactions (swelling, abdominal pain, rash). We describe a 35-year-old man presenting with upper-airway AE progressing rapidly and promptly required cricothyroidotomy. Complement and autoantibody screening together with sequencing of SERPING1 were performed and gave the diagnosis of acquired complement C1 esterase inhibitor deficiency. The patient is unusual to have this disease before the age of 40 years. No associated comorbidities were found. It is important to know that antiallergic medication is not effective in BK-mediated AE.
- 4 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e231122
Open AccessAcquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance
Angioedema (AE) is caused by a wide range of diseases and pharmaceuticals; it can become life-threatening when located to the airways. Patients with deficiency or malfunction of complement C1 esterase inhibitor (hereditary or acquired) experience recurrent AE due to an accumulation of the vasoactive mediator bradykinin (BK). Complement C1 inhibitor normally decreases BK production, so a reduced function hereof causes increased levels. The diagnosis of hereditary or acquired AE can be difficult due to similarities to allergic reactions (swelling, abdominal pain, rash). We describe a 35-year-old man presenting with upper-airway AE progressing rapidly and promptly required cricothyroidotomy. Complement and autoantibody screening together with sequencing of SERPING1 were performed and gave the diagnosis of acquired complement C1 esterase inhibitor deficiency. The patient is unusual to have this disease before the age of 40 years. No associated comorbidities were found. It is important to know that antiallergic medication is not effective in BK-mediated AE.
- 1 January 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 96, 142-146
White blood cell mitochondrial DNA copy number is decreased in rheumatoid arthritis and linked with risk factors. A twin study
- 1 January 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 96, 142-146
White blood cell mitochondrial DNA copy number is decreased in rheumatoid arthritis and linked with risk factors. A twin study
- 12 October 2018
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 30 (1) , 136-139
CD18 is redundant for the response to multiple vaccines: A case study
- 12 October 2018
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 30 (1) , 136-139
CD18 is redundant for the response to multiple vaccines: A case study
- Open Access
- 3 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Hereditary angioedema: a mother diagnosing her child using Google as a diagnostic aid
Hereditary angioedema (HAE), due to C1-inhibitor deficiency, is a rare autosomal dominant and potentially life-threatening disease characterised by recurrent oedema attacks of skin, mucosa and viscera. Due to the rarity and the fact that symptoms of HAE imitate other forms of angioedema and other conditions, HAE may be misdiagnosed, especially in emergency settings. Consequently, patients with HAE may experience significant delays in diagnosis. Without an accurate diagnosis patients with HAE may not receive proper treatment. At times ’Doctor Google' may be an important tool in establishing the diagnosis. The aim of this case report is to emphasise the importance of listening to patients and relatives and being humble to ’Doctor Google'. Furthermore, the aim is to remind all healthcare personal of HAE and the importance of considering the rare differential diagnoses to common symptoms.
- 3 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Open AccessHereditary angioedema: a mother diagnosing her child using Google as a diagnostic aid
Hereditary angioedema (HAE), due to C1-inhibitor deficiency, is a rare autosomal dominant and potentially life-threatening disease characterised by recurrent oedema attacks of skin, mucosa and viscera. Due to the rarity and the fact that symptoms of HAE imitate other forms of angioedema and other conditions, HAE may be misdiagnosed, especially in emergency settings. Consequently, patients with HAE may experience significant delays in diagnosis. Without an accurate diagnosis patients with HAE may not receive proper treatment. At times ’Doctor Google' may be an important tool in establishing the diagnosis. The aim of this case report is to emphasise the importance of listening to patients and relatives and being humble to ’Doctor Google'. Furthermore, the aim is to remind all healthcare personal of HAE and the importance of considering the rare differential diagnoses to common symptoms.
- 4 September 2018
- Published by Wiley in Transfusion
- Vol. 58 (10) , 2421-2425
Results of noninvasive prenatal RHD testing in Gestation Week 25 are not affected by maternal body mass index
BACKGROUND: Reliability of noninvasive prenatal RHD genotype test (NIP RHD) depends on having sufficient amounts of cell‐free fetal DNA (cffDNA) in the maternal plasma sample. The fraction of cffDNA in maternal plasma is inversely related to maternal body mass index (BMI), suggesting that high maternal BMI may limit the test's accuracy. This study determined the effect of maternal BMI on the accuracy of NIP RHD.STUDY DESIGN AND METHODS: Results from NIP RHD performed in Gestation Week 25 were correlated to maternal BMI in Week 12. The accuracy of NIP RHD result was determined by correlation with serologic RhD types of the neonates.RESULTS: A total of 1618 pregnancies in 1588 D– women were included. Median BMI in these pregnancies was 24.2 (10%‐90%, 20.1‐32.4), and in 261 of 1618 (16%) pregnancies BMI was 30 or more (median BMI in this group was 33.6; 10th‐90th percentiles, 30.5‐41.1). NIP RHD was positive in 987 of 1618 (61%), negative in 582 of 1618 (36%), and inconclusive in 49 of 1618 (3.0%). Compared to the neonate's serologic RhD type, nine of 987 (0.9%) positive NIP RHD results were false positive, and four of 582 (0.7%) negative NIP RHD results were false negative (FN). In five of 49 (10%) inconclusive NIP RHD results, the neonatal RhD type was positive. There was no difference in median BMI between individuals who tested inconclusive or FN compared to those with true positive or true negative results (p = 0.80).CONCLUSION: The accuracy of NIP RHD testing performed in Gestation Week 25 does not depend on maternal BMI in the 12th gestation week.
- 4 September 2018
- Published by Wiley in Transfusion
- Vol. 58 (10) , 2421-2425
Results of noninvasive prenatal RHD testing in Gestation Week 25 are not affected by maternal body mass index
BACKGROUND: Reliability of noninvasive prenatal RHD genotype test (NIP RHD) depends on having sufficient amounts of cell‐free fetal DNA (cffDNA) in the maternal plasma sample. The fraction of cffDNA in maternal plasma is inversely related to maternal body mass index (BMI), suggesting that high maternal BMI may limit the test's accuracy. This study determined the effect of maternal BMI on the accuracy of NIP RHD.STUDY DESIGN AND METHODS: Results from NIP RHD performed in Gestation Week 25 were correlated to maternal BMI in Week 12. The accuracy of NIP RHD result was determined by correlation with serologic RhD types of the neonates.RESULTS: A total of 1618 pregnancies in 1588 D– women were included. Median BMI in these pregnancies was 24.2 (10%‐90%, 20.1‐32.4), and in 261 of 1618 (16%) pregnancies BMI was 30 or more (median BMI in this group was 33.6; 10th‐90th percentiles, 30.5‐41.1). NIP RHD was positive in 987 of 1618 (61%), negative in 582 of 1618 (36%), and inconclusive in 49 of 1618 (3.0%). Compared to the neonate's serologic RhD type, nine of 987 (0.9%) positive NIP RHD results were false positive, and four of 582 (0.7%) negative NIP RHD results were false negative (FN). In five of 49 (10%) inconclusive NIP RHD results, the neonatal RhD type was positive. There was no difference in median BMI between individuals who tested inconclusive or FN compared to those with true positive or true negative results (p = 0.80).CONCLUSION: The accuracy of NIP RHD testing performed in Gestation Week 25 does not depend on maternal BMI in the 12th gestation week.